Doyle Mittie — SEC Form 4 filings
SEC reporting owner CIK 1918845. 20 Form 4 filings on record with FilingPulse; latest filed 2026-09-01.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2024-07-16 to 2026-09-01. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 17 legs across 12 filings — 151,516 shares, $2,977,830 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 42.
- Largest priced transaction: sale of 44,944 shares @ $21.20 ($952,669) in Avalo Therapeutics, Inc., filed 2026-05-07.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | Chief Medical Officer | 18 | — | 17 legs · 151,516 sh · $2,977,830 | 40 |
| Cullinan Therapeutics, Inc. (CGEM) | Director | 2 | — | — | 2 |
Form 4 filings — Doyle Mittie
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-01 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 679 @ $8.04 · Sale (S): 679 @ $20 · Option exercise (M): 679 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 1,000 @ $12.65 · Sale (S): 1,000 @ $20 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 679 @ $8.04 · Sale (S): 679 @ $20 · Option exercise (M): 679 (derivative) @ $0 | EDGAR |
| 2026-07-29 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 1,000 @ $12.65 · Sale (S): 1,000 @ $20 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 2,875 @ $12.65 · Option exercise (M): 1,779 @ $8.04 · Sale (S): 4,654 @ $20 · Option exercise (M): 2,875 (derivative) @ $0 · Option exercise (M): 1,779 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 1,450 @ $8.04 · Sale (S): 1,450 @ $18 · Option exercise (M): 1,450 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Cullinan Therapeutics, Inc. (CGEM) | Grant/award (A): 21,781 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Avalo Therapeutics, Inc. (AVTX) | Tax withholding (F): 1,084 @ $13.10 | EDGAR |
| 2026-06-01 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 679 @ $8.04 · Sale (S): 679 @ $16 · Option exercise (M): 679 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 43,500 @ $0 | EDGAR |
| 2026-05-19 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 3,000 @ $12.65 · Sale (S): 3,000 @ $18.76 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 1,000 @ $12.65 · Option exercise (M): 679 @ $8.04 · Sale (S): 1,679 @ $16 · Option exercise (M): 77,905 @ $12.65 · Option exercise (M): 28,650 @ $8.04 · Sale (S): 27,538 @ $18.03 · +8 more | EDGAR |
| 2026-04-08 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 3,970 @ $12.65 · Sale (S): 3,970 @ $18.01 · Option exercise (M): 3,970 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 679 @ $8.04 · Sale (S): 679 @ $16 · Option exercise (M): 679 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 19,500 @ $12.65 · Option exercise (M): 5,992 @ $8.04 · Sale (S): 25,492 @ $16.15 · Option exercise (M): 19,500 (derivative) @ $0 · Option exercise (M): 5,992 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Avalo Therapeutics, Inc. (AVTX) | Tax withholding (F): 1,013 @ $4.10 | EDGAR |
| 2025-08-08 | 4 | Cullinan Therapeutics, Inc. (CGEM) | Grant/award (A): 79,456 (derivative) @ $0 | EDGAR |
| 2025-01-30 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 155,000 (derivative) @ $0 | EDGAR |
| 2024-07-16 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 234,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1918845 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →